Operationally in-line 1Q; DFEU drive earnings

Company
19 Aug 2024
5 Min read 
  • Glenmark Pharma's 1QFY25 results update and financials 
  •  Estimate, TP, and rating changes
  •  Financials and valuation overview 
  •  Sales, EBITDA, PAT, ratios, and shareholding pattern
  •  Operational performance and growth levers 
  •  Domestic, US, EU, and RoW markets
  •  Management commentary highlights 
  •  Revenue growth, market potential, and product launches
  •  Upgrade to BUY 
  •  Product mix, lower R&D expenses, and margin improvement
  •  Financials and valuation summary 
  •  Income statement, balance sheet, ratios, and cash flow statement
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority